Parambir S. Dulai
University of California, San Diego
H-index: 50
North America-United States
Top articles of Parambir S. Dulai
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and … | Gut | Emily CL Wong Parambir S Dulai Neeraj Narula | 2023/4/1 |
A serum biomarker panel can accurately identify mucosal ulcers in patients with Crohn’s disease | Inflammatory bowel diseases | Ariela K Holmer Brigid S Boland Siddharth Singh Jennifer Neill Helen Le | 2023/4/1 |
Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease | Alimentary Pharmacology & Therapeutics | Emily CL Wong Parambir S Dulai John K Marshall Vipul Jairath Walter Reinisch | 2022/5 |
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease | Journal of Crohn's and Colitis | Neeraj Narula Emily CL Wong Jean-Frederic Colombel William J Sandborn Marc Ferrante | 2022/4/1 |
Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis | Clinical Gastroenterology and Hepatology | Neeraj Narula Emily CL Wong John K Marshall Jean-Frederic Colombel Parambir S Dulai | 2022/7/1 |
Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity | Nature microbiology | Robert H Mills Parambir S Dulai Yoshiki Vázquez-Baeza Consuelo Sauceda Noëmie Daniel | 2022/2 |
The host-microbiome response to hyperbaric oxygen therapy in ulcerative colitis patients | Cellular and molecular gastroenterology and hepatology | Carlos G Gonzalez Robert H Mills Melissa C Kordahi Marvic Carrillo-Terrazas Henry Secaira-Morocho | 2022/1/1 |
Recommendations for standardizing clinical trial design and endoscopic assessment in postoperative Crohn’s disease | Inflammatory bowel diseases | Jurij Hanzel Vipul Jairath Peter De Cruz Leonardo Guizzetti Lisa M Shackelton | 2022/9/1 |
Clinical decision support tool for infliximab in Crohn’s disease | Clinical Gastroenterology and Hepatology | Parambir S Dulai Emily CL Wong Walter Reinisch Neeraj Narula | 2022/5/1 |
Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic naïve Crohn’s disease | Clinical Gastroenterology and Hepatology | Neeraj Narula Emily CL Wong Parambir S Dulai Neil K Sengupta John K Marshall | 2022/7/1 |
Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT | Clinical Gastroenterology and Hepatology | Jurij Hanzel Christopher Ma Guangyong Zou Siddharth Singh Parambir S Dulai | 2022/1/1 |
Spatial evolution of histologic and endoscopic healing in the left and right colon in patients with ulcerative colitis | Clinical Gastroenterology and Hepatology | Sushrut Jangi Ariela K Holmer Parambir S Dulai Brigid Boland Mark Valasek | 2022/4/1 |
Modeling endoscopic improvement after induction treatment with mesalamine in patients with mild-to-moderate ulcerative colitis | Clinical Gastroenterology and Hepatology | Christopher Ma Jenny Jeyarajah Leonardo Guizzetti Claire E Parker Siddharth Singh | 2022/2/1 |
Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND … | Parambir S Dulai Victoria Rai Laura E Raffals Dana Lukin David Hudesman | 2022/8/1 | |
A clinical prediction model to determine probability of response to certolizumab pegol for Crohn’s disease | BioDrugs | Pavine LC Lefevre Parambir S Dulai Zhongya Wang Leonardo Guizzetti Brian G Feagan | 2022/1/1 |
Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease | Chung Sang Tse Parambir S Dulai | 2022/6/1 | |
Ulcerative colitis: clinical manifestations and management | Yamada's Atlas of Gastroenterology | William F Stenson William J Tremaine Russell D Cohen | 2016/2/19 |
Digital therapeutics care utilizing genetic and gut microbiome signals for the management of functional gastrointestinal disorders: Results from a preliminary retrospective study | Frontiers in Microbiology | Shreyas V Kumbhare Patricia A Francis-Lyon Dashyanng Kachru Tejaswini Uday Carmel Irudayanathan | 2022/3/21 |
Comparative risk of serious infections with tumor necrosis factor α antagonists vs vedolizumab in patients with inflammatory bowel diseases | Clinical Gastroenterology and Hepatology | Siddharth Singh Herbert C Heien Jeph Herrin Parambir S Dulai Lindsey Sangaralingham | 2022/2/1 |
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel … | Alimentary Pharmacology & Therapeutics | Niels Vande Casteele William J Sandborn Brian G Feagan Séverine Vermeire Parambir S Dulai | 2022/8 |
